Vandetanib

An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
BACKGROUND No effective standard treatment exists for patients with radioiodine-refractory, advanced differentiated thyroid… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
PURPOSE Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor, epidermal growth factor… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2011
Highly Cited
2011
PURPOSE Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor and epidermal growth factor… (More)
Is this relevant?
Highly Cited
2011
Highly Cited
2011
PURPOSE Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor and epidermal growth factor… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BACKGROUND Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor (VEGFR), epidermal growth… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
PURPOSE There is no effective therapy for patients with distant metastasis of medullary thyroid carcinoma (MTC). Activating… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
PURPOSE Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor-2 and epidermal growth factor… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2009
Highly Cited
2009
PURPOSE Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
PURPOSE Vandetanib is a once-daily, oral inhibitor of vascular endothelial growth factor receptor and epidermal growth factor… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
PURPOSE Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor-2 and epidermal growth factor… (More)
Is this relevant?